Citi adjusts target to AUD 22.00 for Telix stock

Published on 10/20/2026 at 19:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue reached USD 477.40 million. Telix stock costs EUR 9.86 on October 20, 2026. The ASX closed at AUD 15.76 that day.

Analyst target and operating figures

Citi adjusted its Telix target to AUD 22.00 on October 19, 2026.
First-half 2026 revenue reached USD 477.40 million.
Telix stock costs EUR 9.86 at Lang & Schwarz on October 20, 2026 at 7:00 p.m. CEST.
Telix had an AUD 5.4 billion market capitalization on October 20, 2026.

Telix, AU000000TLX2, Illustration mit AI erstellt.

Telix Pharmaceuticals (ISIN AU000000TLX2) has a new AUD 22.00 analyst target from Citi, while its euro quotation stood at EUR 9.86 at Lang & Schwarz on October 20, 2026 at 7:00 p.m. CEST. MarketScreener reported the target adjustment on October 19, 2026. At the ASX, Telix closed at AUD 15.76 on October 20, 2026.

Target leaves room for execution

Citi's AUD 22.00 target stands 39.59 percent above the ASX price of AUD 15.76 on October 20, 2026. The source names the new target but does not provide an earlier Citi target, so the comparison is with the quoted ASX price rather than a prior estimate. The valuation case therefore rests on continued delivery from Telix's commercial radiopharmaceutical portfolio and development pipeline.

Telix's latest reported operating figure was first-half 2026 revenue of USD 477.40 million, up 22.00 percent from the prior-year period. Simply Wall St also reported net income of USD 38.30 million and a profit margin of 8.00 percent for the first half of 2026. Those figures give the target a fundamental counterweight, although the same report identified debt coverage and one-off items as risks.

Stock position and valuation

Telix's ASX price of AUD 15.76 remained below its 52-week high of AUD 18.22 and above its 52-week low of AUD 8.26 on October 20, 2026. Its market capitalization was AUD 5.4 billion, and its price-to-earnings ratio was 122.93 on the same date. The company does not pay a dividend according to the quoted market data.

Comparison with peers

Telix: up 2.34 percent, P/E 122.93, market capitalization AUD 5.4 billion.

ResMed: up 0.38 percent, P/E 23.57, market capitalization AUD 48.1 billion.

CSL: up 1.16 percent, P/E minus 25.92, market capitalization AUD 94.2 billion.

Pipeline expansion adds a second test

On October 19, 2026, Telix announced a collaboration with Ekalia to develop U.S. production of astatine-211, beginning with a cyclotron installation near Philadelphia. Grafa reported that the facility is intended to support TLX102-Tx research and provide longer-term isotope access. The announcement adds manufacturing and supply-chain execution to the commercial growth question already reflected in the analyst target.

Euro quotation for German investors

For German investors, Telix was trading at EUR 9.86 at Lang & Schwarz on October 20, 2026 at 7:00 p.m. CEST in after-hours trading. The ASX session had closed at AUD 15.76 on October 20, 2026, while Telix's 52-week range was AUD 8.26 to AUD 18.22.

The further course of trading is shown by the continuously updated real-time quote of Telix stock.